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Abstract
Funding bodies have recently introduced a requirement that data sharing must be a consideration of
all funding applications in genomics. Like all new developments this condition has had an impact
on scientific practice, particularly in the area of publishing and in the conduct of research. We discuss
the challenges that must be addressed if the full benefits of data sharing, as envisaged by funders,
are to be realised.
The field of genomics is regarded as a leader in the development of infrastructure, resources
and policies that promote data sharing.1 Examples include the Human Genome Project and the
HapMap project — which promote the sharing of sequence data — and the more recent data-
sharing structures for genome wide association studies (GWAS), such as dbGaP and the
European Genotyping Archive 2 Rapid developments in genomics are widely promoted as
being dependent upon such resources, which can be accessed by many researchers for different
research uses. They are regarded by many as testimony to the success of the principle of open
access. In addition, all of the large funding bodies now make data sharing a requirement of
support for all projects, including all hypothesis-driven projects, whose primary purpose is to
focus on a specific research question rather than to create data to be used by others. The rationale
for these policies is that science and creativity are furthered by access to openly available data,
and that data created by publicly funded bodies should be freely available in the research
community. While these policies are still in their infancy, their impact is starting to be felt on
the planning, execution, and oversight of genomics research, and on the way in which results
are disseminated.
Through our empirical work with scientists in the field,3 we have identified some key areas of
scientific practice that are being affected by these policies. In this paper we discuss these four
areas: the difficulties of acknowledging individual contributions to the generation of data; the
way that these policies change the responsibilities towards participants; the implications that
this has for maintaining public trust; and the new mechanisms that have been developed for
oversight of access to data. These important issues illustrate the tensions that data-sharing
policies create for researchers, who must fulfil the requirements of funding bodies, while also
protecting research participants and their own career development. Failure to understand these
particular tensions and the effect of these policies on scientific practice may have a detrimental
impact on global good will and trust in genomics research and on the development of
sustainable data sharing practices. Consideration of these issues is timely, as the effects of data
sharing policies are starting to be visible and understood, but are also being re-examined, as
in the recent case where genotypic data were withdrawn from internet access by the NIH and
the Wellcome Trust.4-6
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Changes in scientific practice
The data sharing policies of funders build on and accelerate changes that have been occurring
over the last two or three decades in the way that biomedical science is carried out and scientific
data are generated and analysed. In genomics, change has been driven primarily by the need
for fundamental sequence information, comparative populations, large numbers of samples,
and by the falling costs and increasing capacity of sequencing and computing technologies.
Research practice has become increasingly interdisciplinary,7 with the rapid formation of
flexible and dynamic research collaborations around the world.8 For example, the use of new
methodology such as GWAS requires large numbers of clinically well-characterised samples
to be collected from patients; laboratory staff and researchers to manage the genotyping
pipeline; bioinformaticians, statisticians and other data analysts to interpret the data; and
leadership from principal investigators. In combination, these factors have had a significant
effect on the way that research projects are planned, organised and managed, and have
encouraged the development of open access policies (BOX 1).
Hypothesis-led projects
In the case of new hypothesis-led projects, researchers are required to provide, in their funding
proposal, a plan for how data and results will be shared. The specific aim of data sharing policies
is to ensure maximum availability of data. Arguments can be made for excluding access to the
data by some researchers on the basis of the sensitivity of the data, or the potential to identify
or stigmatise individuals or groups. While newly funded projects can be planned and developed
in accordance with data sharing policies, greater challenges arise, as is indeed happening, when
such policies are applied retrospectively to completed projects or to ongoing longitudinal
projects.
Large-scale, data-generation projects
Advances in sequencing and computing technologies have also enabled the scientific
community to embark on a new type of scientific effort, specifically large-scale, data-
generation projects. Such projects generate data and create management infrastructures, or
platforms, which can support simultaneous access to a dataset by multiple researchers.
Secondary users of the data are far removed from the researchers who carried out the collection
of the samples and data, as well as from the research participants. In such projects, research
participants are informed that the analysis of their sequence will be freely available on the web.
These projects have enormous benefits for the entire scientific community, as they have
accelerated the creation of new knowledge and provided a blueprint for data sharing (BOX 2).
The changing landscape of data sharing
The data sharing policies of funders may crystallise and encourage existing trends in scientific
practice. In the past, data sharing has primarily been done with known colleagues, based on
mutual respect, trust and a common interest. The conditions of access would be negotiated on
an individual basis and would vary according to particular circumstances. Funders now require
that data sharing be considered in every newly funded research project, unless there are
justifiable reasons why this should not be so. With these policies, the question for many
researchers has become how to share data, whereas previously it was whether data should be
shared at all. This creates a number of challenges for several areas of scientific practice. We
begin by discussing how best to provide rewards and incentives for the researchers who have
been involved in data generation.
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Acknowledging individual contributions
In the past, a dataset would have been used primarily by the researchers who had created it,
and would provide the basis for many publications. There would have been a direct relationship
between the creation of the data and control over usage and the publication of results. However,
with data sharing policies, the fact that particular researchers have created a dataset no longer
gives them an enduring priority or control over its use and resulting publications. The challenge
then is how to reward and acknowledge the production of a dataset.
Proper recognition for authors and contributors
The traditional form of acknowledgement is through a publication, which is also a key way of
ensuring career advancement. Guidelines for many journals require that data production should
be acknowledged, but how this is done is largely left up to individuals following the norms
that exist within different disciplines. One solution has been to publish articles with large
numbers of authors,9 recognising the involvement of many researchers and data producers in
large collaborations. A difficulty arises when the number of authors becomes excessive, as
authorship is more a reflection of contribution to a project rather than to a publication. The
practice adopted by some publications is to describe the contributions of individual authors,
although this policy is difficult to extend to large numbers of authors. An alternative means
might be to making a distinction between a ‘contributor’ — who has provided the dataset—
and an ‘author’ — who has worked on the analysis or result.
Means of recognition other than traditional authorship have also been proposed.10 In one
approach, the dataset itself would be recognised in the publication according to an established
system. This would acknowledge use of the dataset and indirectly reward the contributions of
those who have been instrumental in establishing the resource, without needing to cite each
contributor to the generation of the dataset. Recognition in a publication is essential but data
generation needs to be established as an activity worthy of recognition in its own right, which
relies on specialist skills. Therefore, it is important that the efforts of data generators are
appreciated by the scientific community, and the establishment of a resource for other
researchers is considered as a valuable output by institutions. In addition, there must be indices
which can also be included in national assessment schemes, such as the Research Assessment
Exercise (RAE) in the UK, which ranks institutions according to their research excellence.
Promoting data sharing
Although publications and formal recognition are important, incentives to share data also need
to be built into the research process. One solution developed by the Genetic Association
Information Network (GAIN) (see BOX 2), is to give the producers of the data a six month
publishing lead on their competitors, even though the data are available to all bona fide
researchers during this time. The researchers that generate the data are given the opportunity
by funders to develop a dataset using new GWA technology. However, this incentive can also
place enormous pressure on the research team who are generating data as well as attempting
to analyse and publish results within a short time span. Working constantly against rapidly
impending deadlines is not in the long run a productive climate, and an extension of such
publishing lead times should be considered. Such incentives require careful thought, as they
are having a significant effect on the way that science is being conducted, both in terms of
teamwork and in the speed of data generation.
Novel ways of acknowledging contributions to the generation of data are required, which are
fair and transparent, lest researchers obstruct data sharing. Genomic data is only useful for
subsequent analyses if it is accompanied by good metadata that describes, for instance, sample
collection procedures, clinical definitions of the cases, and demographic data. In practice,
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therefore, scientists can retain some measure of control over access,11 for example, by claiming
that part of the dataset is not ready to be shared. This would make it difficult for other
researchers to do meaningful analyses.12 This is contrary to the principles of data sharing and
very hard to guard against. However, it would be inappropriate and cumbersome to develop
punitive oversight mechanisms to ensure this does not happen. Instead, ‘carrots’ rather ‘sticks’
need to be used to encourage those that create metadata to share with others further downstream
in the scientific process.
Such incentives need to replicate the climate of trust and reciprocity that accompanies
traditional and more informal data sharing. No one wants to be part of a system where they
feel someone else can take advantage of their unsung contributions. One way forward is to
have an open and honest debate within the scientific community on how and why data sharing,
both formal and informal, works or does not work. This debate is necessary to articulate the
norms required in specific situations to determine a fair and equitable way to share data but
also acknowledge individual contributions. This is not a matter of more regulation and
guidelines, but developing norms that become an intrinsic part of a new scientific culture, in
which people can trust each other because the rules and obligations are known at the outset.
Responsibilities towards study participants
The original context in which the samples and data are collected is associated with expectations
and relationships that are understood both by researchers and participants.13 Researchers may
feel a strong sense of responsibility for ‘their’ samples and feel a legal and moral responsibility
for research participants that often extends beyond the original terms of consent. This
responsibility may not be felt by secondary researchers who have no connection with the
research participants, and see themselves as only dealing with data. While secondary
researchers have an obligation to use data in a scientifically sound, ethical and lawful manner,
these obligations are not the same as the researchers enrolling patients in a study. Informed
consent forms, which try to be succinct, may not embody all of the expectations that are
associated with enrolment in a study and an on-going clinical relationship, and may leave room
for differing interpretations of the scope of consent.
In data-sharing policies, researchers are given the opportunity to justify why raw data should
not be shared. Given their knowledge about the types of uses that may be made of data, based
on the original consent, researchers are in a good position not only to decide on appropriate
uses, but also to protect against possible misuse. In particular, when samples are collected and
analysed as an extension to ongoing epidemiological work, cohort studies, or disease-specific
work where the relationship develops in a clinical setting, the obligation to share genomic data
may be perceived as an imposition on the relationships that have been built up between
researchers and participants.
The challenge for funders is to ensure that this sense of stewardship is respected, by ensuring
that new systems for sharing data acknowledge these perceived responsibilities. There is a
danger that data sharing policies may be experienced as being punitive, or that those who feel
uncertain about sharing may be characterised as obstructive and short-sighted. However,
reluctance to share may have sound justifications. These claims should not be automatically
dismissed as researchers being territorial. Such concerns cannot be ignored, as they can have
practical as well as ethical implications in a project, where the trust and support of participants
is vital. In addition, researchers who are perceived to be uncooperative could be excluded from
key areas of activity, such as developing strategic policies and being involved in peer-review.
Funding bodies must be prepared to consider the claims of those for whom data sharing,
because of the nature of their research and situation, may create difficulties. At the moment,
requests for exemption from data sharing are judged by funders but it may be better for this
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assessment to be made by bodies which are independent from considerations about future
funding for the applicants.
Maintaining Public Trust
The mechanisms that have traditionally been used to protect research participants are informed
consent and the anonymisation of datasets. However, the sharing of data from genomic studies
tests the effectiveness of these standard mechanisms of privacy protection.
Anonymisation of data
The digital revolution, which has allowed many types of data to be shared both with and without
consent, is rapidly changing the landscape of privacy protection. Procedures for controlling
disclosure, such as coding each study subject or aggregating the information, can be employed
to protect the identity of data subjects. However, these policies may lessen the scientific utility
of the data, as fine detail and nuances can be lost in the effort to protect privacy.14 Furthermore,
as DNA is a unique identifier, it is impossible to completely anonymise a sample, and relatively
small numbers of SNPs can be used to identify individuals.15 The recent decisions by the
Wellcome Trust and the NIH to remove SNP data from publicly accessible databases, following
the paper by Homer and others,16 illustrate the problems of protecting participants' privacy
interests whilst using GWAS methodology. Homer and his colleagues established by a
statistical analysis that an individual could be identified in aggregate data, as genome-wide
scans provide such a wide range of unique data points.
Informed consent
The process of obtaining informed consent is one way for research participants to have some
control over how their information is used: however, this procedure is problematic when it is
applied in a data sharing context.
First, it is difficult to achieve the level of understanding required for truly informed consent,
17 -19 especially where data sharing in genomics is concerned: participants have a variable
understanding of whether their sequence data will be shared, and with whom.20 Second, it is
difficult to provide information about all the potential users of shared data, without a constantly
updated system to inform participants. Many long-term studies, such as the Avon Longitudinal
Study (ALSPAC) have approached this problem through web sites for participants that enhance
an understanding of the science. Greater patient involvement in the decision-making of
biobanks has also been proposed in order to compensate for this deficit. 21 (BOX 3)
Data sharing challenges existing mechanisms for privacy protection. Once data have been
released into the public domain, participants and researchers have little or no control over their
usage, or the possibility that they may be linked to other data sets. Research participants can
exercise only consent or withdrawal: however, it is difficult for participants to control how
their genomic data will be shared – typically they are required to consent to all data sharing
between researchers or none. In addition, there are real doubts whether an individual's request
for withdrawal can be meaningful, due to the complexity of retracting data through different
datasets. In this new context of global data-sharing, better methods of informing participants
about the use of their personal information for different research purposes need to be developed.
Oversight of Access
Data sharing raises new dilemmas for the oversight of research and for the bodies that have
been entrusted to ensure that research is well governed. Traditionally, approval for research is
obtained from a research ethics committee by a particular individual or research group. This
committee holds the principal applicant responsible for monitoring the use of samples and data;
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however, when samples are transported across national borders, and when data are analysed
by people who bear no relation to the original research project or participants, it is virtually
impossible to continue to hold the original collector responsible in the same way. Therefore it
is difficult for research ethics committees to exert their original mandate to ensure the ethical
conduct of research.
It has recently been suggested that ethics committees could have an important function in
monitoring the particular ethical aspects of GWA studies. Although such responsibilities have
mainly focused on the consent process24 and on approving the re-use of samples,25 some have
also considered the potential contribution that ethics committees could make to regulating data
access.26,27 However, ethics committees are already facing increasing challenges in reviewing
complex research proposals28, and it is therefore not clear how already over-burdened
committees could take on the role of monitoring and approving data access –a task that requires
significant insight into the techniques used to produce and analyse data in genomics.
Instead of relying on research ethics committees, some data sharing initiatives have established
specialist advisory bodies, or ‘data access committees’, to determine who should have access
to data and on what grounds. These decisions are not applied uniformly, and the criteria for
decision-making are still in their infancy. However, many of the publicly available criteria for
determining access seem to involve establishing whether a scientist is a ‘bona fide researcher’,
rather than considering whether access will have an effect on research participants. The criteria
to qualify as a ‘bona fide researcher’ are still being developed but could include type of research,
or are simply based on verifying an individual's credentials such as institutional affiliation. In
the case of the NIH dbGaP users are granted a Data Use Certificate which allow access to
several datasets. While this generic authorisation may be efficient, there is the possibility that
the privacy interests of research participants may be overlooked when a number of datasets are
linked together (BOX 4).
Conclusions
Data-sharing policies have been in place in the USA for the past six years and in the UK for
approximately three years, and their full effect on scientific practice is just starting to be
understood. The challenge for individual researchers is to simultaneously fulfil the
requirements of funding bodies, honour their obligations to study participants, and protect their
own interests and careers. The challenge for funders is to ensure that public trust is maintained
and that data sharing policies improve the transfer of research results and knowledge. To ensure
that this framework is sustainable, good working relations are required between funders,
collaborating groups of scientists and the many thousands of recruits that will be needed in the
future.
Establishing and maintaining global public goodwill and trust is an ongoing task to ensure the
future of sound, and hence ethical, scientific research. Meeting such challenges is necessary
to ensure that data sharing practices and policies continue to produce the harvest of tangible
benefits currently enjoyed by some of the scientific community. However, further research and
thought is required to address some of the challenges to scientific practice that data sharing
creates.
BOX 1
Data Sharing Policies
Open access to data is believed to accelerate advances in science, by making data freely
available to all, while also ensuring the expedient use of existing resources that have been
funded by the public purse. The first international document to embody this perspective and
lay out the principles for open access in the field of genomics was the Bermuda Agreement
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in 1996, which was followed by the Fort Lauderdale Agreement in 2003. These documents
together set out the key principles which now dominate thinking and practice regarding
open access to genome sequence data in North America and the UK.
The key idea being promoted in the Bermuda Agreement is that the pre-publication genome
sequence ‘should be freely available and in the public domain in order to encourage research
and development and to maximise its benefit to society.’ The Fort Lauderdale Agreement
took this further by setting out a plan of ‘tripartite responsibility’ for sequence producers,
users and funders for the establishment of ‘community resources’ to achieve rapid and open
data release. This agreement stated that ‘community resource data sets benefit the users
enormously, giving them the opportunity to analyse the data without the need to generate
it first. The data sets are, in general, much larger, richer and of higher quality than individual
laboratories could normally generate.’ Such datasets have been presented as the ‘drivers of
progress in biomedical research’ and therefore they should be ‘made immediately available
for free and unrestricted use by the scientific community to engage in the full range of
opportunities for creative science.’
The open access principles underlying these developments have since been applied by
national funding bodies beyond projects which generate sequence data to other areas of
biomedical research. Examples of such policies are those of the National Institute of Health
(NIH 2003), Genome Canada (2005), and the UK Medical Research Council (MRC 2006).
All of these organisations now make data sharing a requirement of funding in genomics.
These policies have created a climate in which data sharing has become the default, and
applicants must demonstrate why their data should be exempt from the requirement that it
should be deposited for use by other scientists.
BOX 2
Data Generating Projects and Access Criteria
Open access policies
Several data-generating projects provide free access to data online. For example, the Human
Genome Project (1990-2003) aimed to sequence the 3 billion base pairs in the human
genome and to identify all 20,000-25,000 genes. The HapMap Project (2002-2005)
identified chromosome regions with sets of strongly associated SNPs, the haplotypes in
those regions, and the SNPs that tag them. The 1000 Genomes Project (which began in
2007) will develop a map of biomedically relevant DNA variations at unprecedented
resolution.
Each of these projects has relied upon the co-operation of funders and researchers from
many disciplines, and has drawn on considerable resources, expertise and time. As none of
these projects provides any link to phenotypic information, access to the data is freely
available through the internet, regardless of intended use of the data or identity of the user.
Restricted access policies
By contrast, projects that generate, combine and archive different kinds of data, such as
dbGaP, the Genetic Association Information Network (GAIN), and the Wellcome Trust
Case Control Consortium (WTCCC), have developed data release policies to control access.
Some data are placed on the web, but researchers must establish their credentials before
they are allowed access to information that could potentially identify research participants.
The dbGaP is a repository of four types of data: study documentation; phenotypic data;
genetic data (including study subjects' individual genotypes); and statistical results,
including some association and linkage analyses. dbGaP provides two levels of access -
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open and controlled - to allow broad release of non-sensitive data, while providing oversight
and investigator accountability for data sets involving personal health information. The
benefit of dbGAP is that it provides a controlled archiving system for research data.
GAIN (2006-2008) completed an ambitious program to genotype existing research studies
in six major common diseases, and to combine results with clinical data to create a
significant new research resource. The resulting data are being deposited in a database
within the National Library of Medicine at NIH, funded by GAIN, for the broad use of the
research community. Originators of the initial studies received additional grants to make
their own analyses. Access is controlled by an NIH data access committee.
The WTCCC (2007-) is a collaboration of 24 geneticists based in the UK that is analysing
thousands of DNA samples from patients to identify common genetic variations for different
diseases. Aggregated data are placed on the internet, but access to the more detailed
genotypic and phenotypic data is obtained only through the principal investigator, who can
also decide on further collaboration.
The primary goal of all these initiatives is to make data as widely available as possible to
further scientific progress. However, decisions about access are centralised and are no
longer controlled by the research team who collected the data; instead researchers must
conform to specific deposition and access requirements, which in turn affects the way in
which research is conducted.
BOX 3
Consent
Models such as broad consent have been proposed as a solution to some of the ethical
challenges of data sharing. In broad consent, an individual gives consent to widely specified
research, which allows for many future uses of tissue and data rather than just the one (or
more) use(s) specified by known researchers. Once individuals give consent, they are not
re-contacted concerning new uses. In projects where there is uncertainty about the scope of
the consent, authorisation for the use of coded samples and data may be given by a research
ethics committee.
However, there is concern about whether this practical solution to the issue of informed
consent is compliant with data protection principles,22 which require that the individual
should know how, and by whom, their data are being processed.
There is also concern that a broad consent undermines one of the fundamental principles of
medical research, that of individual autonomy and the right of individuals to decide the
nature of their involvement in medical research.23 There are differing conceptions of
autonomy, however; in some views, individual autonomy requires decisions to be based
upon full information; according to others, full information is not required for autonomous
consent as long as individuals understand the broad nature of what is proposed and
understand that they do not have all the details of what is involved. However, this latter
situation demands a greater level of trust in the individuals and institutions concerned.
BOX 4
Global Data Sharing
Organisations such as P3G, the Biobanking and Biomolecular Resources Research
Infrastructure (BBMRI), and the Organization for Economic Cooperation and Development
(OECD) have started the legal analysis that is required to develop mechanisms that promote
global data-sharing while at the same time ensuring that research is carried out ethically
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and according to accepted standards. Ideally, the new framework would relieve researchers
from having to seek approval from multiple data access committees, but this direction is
still being debated. One possibility is the development of a system where an approval for
access is given by one international body for a number of similar projects rather than having
independent access committees for each project. This could develop uniformity in decision-
making and create a clear and transparent set of criteria for deciding questions of access for
all researchers. The disadvantage is that it removes decision-making from the local level to
a body that is removed from the context in which the dataset has been established.
One of the problems of such a proposition is that while international agreements can help
to set broad standards, all countries have their own systems of law. This means the flow of
data and samples through a number of countries will be subject to many different legal
regimes, and to different sets of guidelines and standards. The concept of an international
body to oversee data sharing is good in theory, but in reality it would probably add another
layer of bureaucracy for researchers, as they would be forced to comply with the
international layer of approval, as well as comply with national regulations.
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